Cell and Gene Outsourcing

  1. How To Select The Right Viral Vector For Your Unique Therapy 8/17/2026

    Choosing the wrong viral vector can compromise your therapy's safety and efficacy. Compare AAV, lentivirus, adenovirus, HSV, and emerging types across key manufacturing and clinical factors.

  2. Navigating An Uncertain Regulatory Environment For mRNA-Based Products 8/17/2026

    mRNA developers face a regulatory gap: as of 2024, neither FDA nor EMA has issued CMC-specific guidelines. Learn how early regulator engagement and CDMO partnerships reduce risk.

  3. Pox Virus, VSV And HSV Platforms 8/14/2026

    Advance viral vaccine, gene therapy, and oncolytic programs with insights on scalable manufacturing, analytical testing, and regulatory readiness.

  4. The Impact Of hcDNA Analytics On Bioprocess Performance 8/14/2026

    Reliable hcDNA monitoring can improve bioprocess performance, support compliance, and guide upstream and downstream decisions that impact quality and yield.

  5. Strengthening cIEF Method Validation With cIEF-MS 8/14/2026

    Preparing for method validation, a biopharma company needed to characterize cIEF charge variants and confirm peak identities for regulatory readiness.

  6. Confirming Structural Consistency With HDX-MS 8/14/2026

    To support regulatory confidence, a biopharma company evaluated whether manufacturing changes affected its monoclonal antibody's higher-order structure.

  7. Confident Sialic Acid Identification With MS/MS 8/14/2026

    Traditional mass spectrometry left uncertainty around potentially immunogenic glycans. Learn how a biologics developer achieved regulatory-ready clarity.

  8. Building A Smarter Potency Strategy For Bispecific Antibodies 8/14/2026

    A biotech company needed a regulatory-ready potency strategy for a bispecific antibody. This organization combined orthogonal analytics with functional assays.

  9. Developing A Robust Crystallization Process For A High-Molecular-Weight Peptide 8/14/2026

    Scaling peptide crystallization is complex, with solid forms, polymorphic impurities, and solvent constraints all impacting quality and manufacturability.

  10. Revealing Hidden Integration Events With TLA And Nanopore Sequencing 8/14/2026

    When standard methods fell short, a biotech company used advanced analysis to confirm targeted construct integration and detect hidden genome changes.